There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Savara Inc (SVRA), Aerpio Pharmaceuticals Inc (ARPO) and MacroGenics (MGNX) with bullish sentiments.
Savara Inc (SVRA)
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Savara Inc today and set a price target of $22. The company’s shares closed yesterday at $9.82, close to its 52-week low of $8.41.
Fein wrote:
“Valuation and risks to achievement of target price. Our price target of $22/share is based on an equally weighted composite of: (a) $22/share, as a 30x multiple of taxed and diluted $5.47 discounted back to FY18 at 25% (in line with the expected PE multiple and discount rate of an early development stage biotechnology company); and (b) an NPV of $22/share (discounted cash flow analysis using a 14% discount rate and 2% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company).”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 12.2% and a 45.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
Savara Inc has an analyst consensus of Strong Buy, with a price target consensus of $19.
See today’s analyst top recommended stocks >>
Aerpio Pharmaceuticals Inc (ARPO)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Aerpio Pharmaceuticals Inc, with a price target of $9. The company’s shares closed yesterday at $2.10, close to its 52-week low of $1.85.
Selvaraju observed:
“Our 12-month price target is derived from a market value of the firm at $350M, which includes a discounted cash flow- based asset value for AKB-9778 and AKB-4924, using a 15% discount rate and 2% terminal growth rate, and probabilities of success at 30% and 10%, respectively.”
According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -8.3% and a 30.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Fennec Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aerpio Pharmaceuticals Inc with a $9 average price target.
MacroGenics (MGNX)
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on MacroGenics today and set a price target of $34. The company’s shares closed yesterday at $16.60, close to its 52-week low of $15.48.
Chattopadhyay observed:
“Our 12-month, $34 price target for shares of MacroGenics is based on a 13-year DCF-driven sum-of-the-parts analysis. Our DCF is driven by: beta of 1.68, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 11.5%, and tax rate of 15% beginning in FY 2027. (19%), flotetuzumab (17%) together represent about 99% of our target.”
According to TipRanks.com, Chattopadhyay ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.4% and a 38.7% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Jounce Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for MacroGenics with a $32 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
